Severe cholestasis due to azathioprine in Behcet's disease.
Adult
Azathioprine
/ adverse effects
Behcet Syndrome
/ complications
Chemical and Drug Induced Liver Injury
Cholestasis
/ chemically induced
Humans
Immunosuppressive Agents
/ adverse effects
Jaundice
/ chemically induced
Liver
/ drug effects
Male
Nausea
/ chemically induced
Pruritus
/ chemically induced
Treatment Outcome
Uveitis
/ drug therapy
Vomiting
/ chemically induced
drug interactions
drugs: gastrointestinal system
hepatitis other
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
31 Mar 2019
31 Mar 2019
Historique:
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Azathioprine (AZA) is an immunosuppressive drug that is widely used in the treatment of autoimmune diseases. Although AZA is used widely, many studies reported that AZA-related hepatotoxicity is rather rare. We aimed to present a case with severe cholestatic hepatitis due to AZA use for Behcet's disease. Three weeks after starting AZA for the treatment of uveitis, the patient was admitted to our clinic with cholestasis and constitutional symptoms. In liver biopsy, findings were in accordance with drug reaction, and the AZA treatment was stopped. After 2 months, bilirubin levels and liver tests results became normal. As a result, given that AZA may cause severe cholestasis, the drug should be stopped if idiosyncrasy or hypersensitivity develops. If there is a debate in the diagnosis, histopathological evaluation of the liver would be the major issue because of the correct diagnosis of the drug toxicity and excluding other aetiologies.
Identifiants
pubmed: 30936327
pii: 12/3/e226340
doi: 10.1136/bcr-2018-226340
pmc: PMC6453262
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Azathioprine
MRK240IY2L
Types de publication
Case Reports
Journal Article
Langues
eng
Informations de copyright
© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur J Gastroenterol Hepatol. 2004 Feb;16(2):207-12
pubmed: 15075996
Pharm World Sci. 2010 Dec;32(6):701-3
pubmed: 20972624
Dig Liver Dis. 2009 Dec;41(12):914-5
pubmed: 19376754
Liver. 1991 Apr;11(2):89-93
pubmed: 2051906
Gastroenterol Clin Biol. 2004 Aug-Sep;28(8-9):720-59
pubmed: 15646539
Dig Dis Sci. 2012 Jun;57(6):1717-8
pubmed: 22526581
Gut. 1991 Jun;32(6):715-7
pubmed: 2060883
J Dermatolog Treat. 2010 Nov;21(6):357-60
pubmed: 20443662
J Clin Gastroenterol. 2017 Jan;51(1):63-69
pubmed: 27648552
Arq Gastroenterol. 2012 Apr-Jun;49(2):130-4
pubmed: 22767000
Can J Gastroenterol. 1998 Oct;12(7):479-83
pubmed: 9812167
Gastroenterology. 1984 Jan;86(1):162-5
pubmed: 6689657
Scand J Gastroenterol. 2017 Aug;52(8):876-880
pubmed: 28388864
Ann Rheum Dis. 1990 Jan;49(1):25-7
pubmed: 2138007
Postgrad Med J. 1980 Apr;56(654):274-5
pubmed: 7433331
Br Med J. 1974 Jan 12;1(5897):49-51
pubmed: 4812392
Clin Exp Rheumatol. 2005 Jul-Aug;23(4):532-9
pubmed: 16095126
Yonsei Med J. 1997 Dec;38(6):401-10
pubmed: 9509910
Indian J Pharmacol. 2011 Nov;43(6):733-5
pubmed: 22144788